GLP-3 Research Compound

Description

Retatrutide (LY-3437943) Research Peptide

Retatrutide is a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. This triple receptor mechanism distinguishes it from dual-agonists like tirzepatide, making it one of the most studied investigational peptides in metabolic research.

Research Profile

• Targets: GLP-1R, GIPR, GCGR (triple agonist)
• Molecular Weight: ~4,605 Da
• Purity: ≥98% by HPLC
• Form: Lyophilized powder
• Storage: -20°C, protect from light

Published Research

Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated significant findings in metabolic research endpoints. The compound has been studied across multiple dose ranges in controlled research settings.

Handling

Reconstitute with bacteriostatic water. Store reconstituted solution at 2-8°C. Use within 30 days of reconstitution. All products are sold strictly for in-vitro research and laboratory use only.